| Reference | FOI 2024-304 |
|---|---|
| Description | Treatment of haematology |
| Date Requested | 06/08/24 |
| Date Replied | 23/08/24 |
| Category | Cancer Treatment Drug Treatment Blood Sciences |
Request
I am conducting analysis on the treatment of haematology in secondary care and kindly request your help.
I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2024 to the end of June 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.
MYELOPROLIFERATIVE DISEASES
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the
3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
1.1 Fedratinib (Inrebic) |
|
|
|
1.2 Momelotinib (Omjjara) |
|
|
|
1.3 Ruxolitinib (Jakavi) |
|
|
|
1.4 Hydroxycarbamide |
|
|
Q2 How many patients were treated for the following myeloproliferative diseases in the
3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Diagnosis with ICD10 codes |
|
Number patients treated |
|
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3 |
|
|
|
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3 |
|
|
|
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3 |
|
|
|
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1 |
|
|
Q3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
3.1 Fedratinib (Inrebic) |
|
|
|
3.2 Momelotinib (Omjjara) |
|
|
|
3.3 Ruxolitinib (Jakavi) |
|
|
|
3.4 Hydroxycarbamide |
|
|
|
3.5 Peginterferon Alfa-2a (Pegasys) |
|
|
|
3.6 Ropeginterferon Alfa-2b (Besremi) |
|
|
|
3.7 Epoetin alfa (Eprex, Binocrit) |
|
|
|
3.8 Epoetin beta (NeoRecormon, Mircera) |
|
|
|
3.9 Epoetin zeta (Retacrit) |
|
|
|
3.10 Darbepoetin (Aranesp) |
|
|
|
3.11 No active treatment |
|
|
|
3.12 Allogeneic stem cell transplant |
|
|
Q4. How many patients were treated with ruxolitinib (Jakavi) in combination with epoetin in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
Please include all types of epoetin – epoetin alfa, epoetin beta, epoetin zeta, darbepoetin alfa
|
Name of medicine |
|
Number patients treated |
|
4.0 Ruxolitinib (Jakavi) + epoetin |
|
|
NON HODGKIN LYMPHOMA (NHL) AND CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the
3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
5.1 Acalabrutinib (Calquence) |
|
|
|
5.2 Ibrutinib (Imbruvica) |
|
|
|
5.3 Pirtobrutinib (Jaypirca) |
|
|
|
5.4 Venetoclax (Venclyxto) |
|
|
|
5.5 Zanubrutinib (Brukinsa) |
|
|
Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
6.1 Acalabrutinib (Calquence) |
|
|
|
6.2 Ibrutinib (Imbruvica) |
|
|
|
6.3 Pirtobrutinib (Jaypirca) |
|
|
|
6.4 Venetoclax (Venclyxto) |
|
|
|
6.5 Zanubrutinib (Brukinsa) |
|
|
Q7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of monotherapy or combination |
|
Number patients treated |
|
7.1 Ibrutinib + venetoclax |
|
|
|
7.2 Obinutuzumab + venetoclax |
|
|
|
7.3 Acalabrutinib monotherapy / maintenance |
|
|
|
7.4 Zanubrutinib monotherapy / maintenance |
|
|
|
7.5 Ibrutinib monotherapy / maintenance |
|
|
|
7.6 Venetoclax monotherapy |
|
|
|
7.7 Venetoclax + rituximab |
|
|
MANTLE CELL LYMPHOMA
Q8. How many patients with Mantle Cell Lymphoma – ICD10 code = C831, C83.1 - were treated in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
|
|
Number patients treated |
|
8.0 Treated for Mantle Cell Lymphoma |
|
|
Q8.1 How many patients with Mantle Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
8.1 MaxiCHOP + rituximab + high dose Cytarabine or NORDIC protocol |
|
|
|
8.2 Stem Cell Transplant |
|
|
|
8.3 Rituximab + bendamustine + cytarabine |
|
|
|
8.4 Rituximab + bendamustine |
|
|
|
8.5 Ibrutinib |
|
|
|
8.6 Rituximab + CHOP, Rituximab + CVP or rituximab + other chemo |
|
|
|
8.7 Acalabrutinib + rituximab + bendamustine |
|
|
Response
MYELOPROLIFERATIVE DISEASES
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
1.1 Fedratinib (Inrebic) |
|
<5 |
|
1.2 Momelotinib (Omjjara) |
|
NIL |
|
1.3 Ruxolitinib (Jakavi) |
|
7 |
|
1.4 Hydroxycarbamide |
|
166 |
Q2 How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Diagnosis with ICD10 codes |
|
Number patients treated |
|
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3 |
|
According to iQemo we have 9 patients treating for polycythaemia vera, this will not include the treatment of “low-risk” patient’s who may be treating using low-dose aspirin which would not be prescribed on our systems.
|
|
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3 |
|
According to iQemo we have 22 patients treating for myelofibrosis, this will not include the treatment of patient’s who may be treating using therapies not regularly prescribed on iQemo such as low-dose aspirin.
|
|
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3 |
|
According to iQemo we have 33 patients treating for essential thrombocythemia, this will not include the treatment of patient’s who may be treating using therapies not regularly prescribed on iQemo such as low-dose aspirin. |
|
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1 |
|
According to iQemo we have 134 patients treating for myeloproliferative disease, this will not include the treatment of patient’s who may be treating using therapies not regularly prescribed on iQemo such as low-dose aspirin. |
Q3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
3.1 Fedratinib (Inrebic) |
|
<5 |
|
3.2 Momelotinib (Omjjara) |
|
NIL |
|
3.3 Ruxolitinib (Jakavi) |
|
6 |
|
3.4 Hydroxycarbamide |
|
15 |
|
3.5 Peginterferon Alfa-2a (Pegasys) |
|
NIL |
|
3.6 Ropeginterferon Alfa-2b (Besremi) |
|
NIL |
|
3.7 Epoetin alfa (Eprex, Binocrit) |
|
NIL |
|
3.8 Epoetin beta (NeoRecormon, Mircera) |
|
NIL |
|
3.9 Epoetin zeta (Retacrit) |
|
NIL |
|
3.10 Darbepoetin (Aranesp) |
|
NIL |
|
3.11 No active treatment |
|
<5 |
|
3.12 Allogeneic stem cell transplant |
|
This is not offered at ELHT. |
Q4. How many patients were treated with ruxolitinib (Jakavi) in combination with epoetin in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
Please include all types of epoetin – epoetin alfa, epoetin beta, epoetin zeta, darbepoetin alfa
|
Name of medicine |
|
Number patients treated |
|
4.0 Ruxolitinib (Jakavi) + epoetin |
|
NIL |
NON HODGKIN LYMPHOMA (NHL) AND CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
5.1 Acalabrutinib (Calquence) |
|
29 |
|
5.2 Ibrutinib (Imbruvica) |
|
16 |
|
5.3 Pirtobrutinib (Jaypirca) |
|
NIL |
|
5.4 Venetoclax (Venclyxto) |
|
14 |
|
5.5 Zanubrutinib (Brukinsa) |
|
<5 |
Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
6.1 Acalabrutinib (Calquence) |
|
29 |
|
6.2 Ibrutinib (Imbruvica) |
|
16 |
|
6.3 Pirtobrutinib (Jaypirca) |
|
NIL |
|
6.4 Venetoclax (Venclyxto) |
|
14 |
|
6.5 Zanubrutinib (Brukinsa) |
|
<5 |
Q7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of monotherapy or combination |
|
Number patients treated |
|
7.1 Ibrutinib + venetoclax |
|
5 |
|
7.2 Obinutuzumab + venetoclax |
|
<5 |
|
7.3 Acalabrutinib monotherapy / maintenance |
|
29 |
|
7.4 Zanubrutinib monotherapy / maintenance |
|
<5 |
|
7.5 Ibrutinib monotherapy / maintenance |
|
11 |
|
7.6 Venetoclax monotherapy |
|
NIL |
|
7.7 Venetoclax + rituximab |
|
5 |
MANTLE CELL LYMPHOMA
Q8. How many patients with Mantle Cell Lymphoma – ICD10 code = C831, C83.1 - were treated in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
|
|
Number patients treated |
|
8.0 Treated for Mantle Cell Lymphoma |
|
9 |
Q8.1 How many patients with Mantle Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?
|
Name of medicine |
|
Number patients treated |
|
8.1 MaxiCHOP + rituximab + high dose Cytarabine or NORDIC protocol |
|
NIL |
|
8.2 Stem Cell Transplant |
|
This is not offered at ELHT. |
|
8.3 Rituximab + bendamustine + cytarabine |
|
NIL |
|
8.4 Rituximab + bendamustine |
|
NIL |
|
8.5 Ibrutinib |
|
<5 |
|
8.6 Rituximab + CHOP, Rituximab + CVP or rituximab + other chemo |
|
<5 |
|
8.7 Acalabrutinib + rituximab + bendamustine |
|
NIL |
Requests for information must be made in writing. Telephone requests cannot be accepted. We accept requests in the form of:
- Letter
Send your request to:
Freedom of Information Requests
East Lancashire Hospitals NHS Trust
Information Governance
Corporate Offices Building
Royal Blackburn Teaching Hospital
Haslingden Road
Blackburn
BB2 3HH
Or email: foi@elht.nhs.uk
You must include your full contact details, stating in what format you would like to receive the information.